Upload
jasmine-john
View
448
Download
0
Tags:
Embed Size (px)
Citation preview
D-r Mitova 1
Vaccine 2Vaccine 2
D-r MitovaMU-Sofia
D-r Mitova 2
PoliomyelitisFirst described by Michael Underwood in 1789First outbreak described in U.S. in 184321,000 paralytic cases reported in the U. S. in 1952Global eradication in near future
D-r Mitova 3
PoliovirusEnterovirus (RNA)Three serotypes: 1, 2, 3Minimal heterotypic immunity between serotypesRapidly inactivated by heat, formaldehyde, chlorine, ultraviolet light
D-r Mitova 4
Poliomyelitis PathogenesisEntry into mouth
Replication in pharynx, GI tract, local lymphaticsHematologic spread to lymphatics and central nervous systemViral spread along nerve fibersDestruction of motor neurons
D-r Mitova 5
0 20 40 60 80 100
Percent
Asymptomatic Minor non-CNS illness
Aseptic menigitis Paralytic
Outcomes of poliovirus infection
D-r Mitova 6
D-r Mitova 7
Poliovirus EpidemiologyReservoir Human
Transmission Fecal-oral Oral-oral possible
Communicability 7-10 days before onset Virus present in
stool 3-6 weeks
D-r Mitova 8
Poliovirus Vaccine1955 Inactivated vaccine
1961 Types 1 and 2 monovalent OPV
1962 Type 3 monovalent OPV
1963 Trivalent OPV
1987 Enhanced-potency IPV (IPV)
D-r Mitova 9
Inactivated Polio VaccineContains 3 serotypes of vaccine virusGrown on monkey kidney (Vero) cellsInactivated with formaldehydeContains 2-phenoxyethanol, neomycin, streptomycin, polymyxin B
D-r Mitova 10
Oral Polio VaccineContains 3 serotypes of vaccine virusGrown on monkey kidney (Vero) cellsContains neomycin and streptomycinShed in stool for up to 6 weeks following vaccination
D-r Mitova 11
Inactivated Polio Vaccine
Highly effective in producing immunity to poliovirus>90% immune after 2 doses>99% immune after 3 dosesDuration of immunity not known with certainty
D-r Mitova 12
Oral Polio VaccineHighly effective in producing immunity to poliovirus50% immune after 1 dose>95% immune after 3 dosesImmunity probably lifelong
D-r Mitova 13
Polio Vaccination Recommendations, 1996-
1999
Increased use of IPV (sequential IPV- OPV schedule) recommended in 1996Intended to reduce the risk of vaccine- associated paralytic polio (VAPP)Continued risk of VAPP for contacts of OPV recipients
D-r Mitova 14
Polio Vaccination Recommendations
Exclusive use of IPV recommended in 2000OPV no longer routinely available in the United StatesVAPP eliminated
D-r Mitova 15
Polio Vaccination Schedule
VaccineOPVOPVOPVOPVOPV
Age2 months3 months4 months16months
6 years
MinimumInterval
---4 wks4 wks
D-r Mitova 16
Polio Vaccination Schedule
VaccineIPVIPVIPVIPV
Age2 months4 months
6-18 months4-6 years
MinimumInterval
---4 wks4 wks4 wks
D-r Mitova 17
Schedules that Include Both IPV and OPV
Only IPV is available in the United StatesSchedule begun with OPV should be completed with IPVAny combination of 4 doses of IPV and OPV by 5 years constitutes a complete series
D-r Mitova 18
Polio Vaccination of Adults
Routine vaccination of U.S. residents >18 years of age not necessary or recommendedMay consider vaccination of travelers to polio-endemic countries and selected laboratory workers
D-r Mitova 19
Polio Vaccination of Unvaccinated Adults
IPVUse standard IPV schedule if possible (0, 1-2 months, 6-12 months)May separate doses by 4 weeks if accelerated schedule needed
D-r Mitova 20
Polio Vaccination of Previously Vaccinated Adults
Previously complete seriesadminister one dose of IPV
Incomplete seriesadminister remaining doses in series
no need to restart series
D-r Mitova 21
Polio Vaccine Adverse Reactions
Rare local reactions (IPV)No serious reactions to IPV have been documentedParalytic poliomyelitis (OPV)
D-r Mitova 22
Vaccine-Associated Paralytic Polio
Increased risk in persons >18 yearsIncreased risk in persons with immunodeficiencyNo procedure available for identifying persons at risk of paralytic disease5-10 cases per year with exclusive use of OPVMost cases in healthy children and their household contacts
D-r Mitova 23
Vaccine-Associated Paralytic Polio (VAPP)
1980-1998Healthy recipients of OPV 41%Healthy contacts of OPV recipients 31%Community acquired 5%Immunodeficient 24%
D-r Mitova 24
Polio VaccineContraindications and Precautions
Severe allergic reaction to a vaccine component or following a prior dose of vaccineModerate or severe acute illness
D-r Mitova 25
Polio Eradication
Western Hemisphere certified polio free in 1994Last isolate of type 2 poliovirus in India in October 1999Global eradication goal by 2010
D-r Mitova 26
D-r Mitova 27
At the start of 2010, 9 countries in west and central Africa are considered to have active outbreaks of polio (i.e. cases within the last six months): Burkina Faso, Chad, Guinea, Liberia, Mali, Mauritania, Nigeria, Senegal and Sierra Leone.
October 04, 2011Cases of polio have been reported in China, the country’s first
cases in more than 10 years. All cases were reported in Xinjiang Uygur autonomous region. Genetic sequencing has shown that the poliovirus isolated from these cases most closely resembles wild poliovirus type 1 found in Pakistan during the second half of 2010.
D-r Mitova 28
Distribution of laboratory-confirmed wild poliovirus type 1 cases (N = 476) European Region, 2010 (458 in Tajikistan, 14 in Russia, three in Turkmenistan, and one in Kazakhstan)
D-r Mitova 29
RubellaFrom Latin meaning "little red"
Discovered in 18th century - thought to be variant of measles
First described as distinct clinical entity in German literature
Congenital rubella syndrome described by Gregg in 1941
D-r Mitova 30
Rubella VirusTogavirus
RNA virus
One antigenic type
Rapidly inactivated by chemical agents, low pH, heat and ultraviolet light
D-r Mitova 31
Rubella PathogenesisRespiratory transmission of virus
Replication in nasopharynx and regional lymph nodes
Viremia 5-7 days after exposure with spread to tissues
Placenta and fetus infected during viremia
D-r Mitova 32
Rubella Clinical FeaturesIncubation period 14 days (range 12-23 days)
Prodrome of low grade fever
Lymphadenopathy in second week
Maculopapular rash 14-17 days after exposure
D-r Mitova 33
D-r Mitova 34
Rubella Complications
Arthralgia or arthritischildrenadult female
Thrombocytopenic purpuraEncephalitisNeuritisOrchitis
rareup to 70%
1/3000 cases
1/6,000 casesrarerare
D-r Mitova 35
Congenital Rubella SyndromeInfection may affect all organs
May lead to fetal death or premature delivery
Severity of damage to fetus depends on gestational age
Up to 85% of infants affected if infected during first trimester
D-r Mitova 36
Congenital Rubella Syndrome
DeafnessCataractsHeart defectsMicrocephalyMental retardationBone alterationsLiver and spleen damage
D-r Mitova 37
Rubella Laboratory DiagnosisIsolation of rubella virus from clinical specimen (e.g., nasopharynx, urine)
Significant rise in rubella IgG by any standard serologic assay (e.g., enzyme immunoassay)
Positive serologic test for rubella IgM antibody
D-r Mitova 38
Rubella EpidemiologyReservoir Human
Transmission RespiratorySubclinical cases may transmit
Temporal pattern Peak in late winter and spring
Communicability 7 days before to 5-7 daysafter rash onsetInfants with CRS may shedvirus for a year or more
D-r Mitova 39
Measles
Highly contagious viral illnessFirst described in 7th centuryNear universal infection of childhood in prevaccination eraFrequent and often fatal in developing areas
D-r Mitova 40
Measles Virus
Paramyxovirus (RNA)Hemagglutinin important surface antigenOne antigenic typeRapidly inactivated by heat and light
D-r Mitova 41
Measles Pathogenesis
Respiratory transmission of virusReplication in nasopharynx and regional lymph nodesPrimary viremia 2-3 days after exposureSecondary viremia 5-7 days after exposure with spread to tissues
D-r Mitova 42
Measles Clinical Features
Incubation period 10-12 days
Stepwise increase in fever to 103°F or higherCough, coryza, conjunctivitisKoplik spots
Prodrome
D-r Mitova 43
Measles Clinical Features
2-4 days after prodrome, 14 days after exposureMaculopapular, becomes confluentBegins on face and headPersists 5-6 daysFades in order of appearance
Rash
D-r Mitova 44
D-r Mitova 45
D-r Mitova 46
ConditionDiarrheaOtitis mediaPneumoniaEncephalitisHospitalizationDeath
Percent reported876
0.1180.2
Measles Complications
Based on 1985-1992 surveillance data
D-r Mitova 47
Measles Laboratory Diagnosis
Isolation of measles virus from a clinical specimen (e.g., nasopharynx, urine)Significant rise in measles IgG by any standard serologic assay (e.g., EIA, HA)Positive serologic test for measles IgM antibody
D-r Mitova 48
Measles EpidemiologyReservoir Human
Transmission Respiratory Airborne
Temporal pattern Peak in late winter–spring
Communicability 4 days before to 4 days after rash onset
D-r Mitova 49
MumpsAcute viral illnessParotitis and orchitis described by Hippocrates in 5th century BCEViral etiology described by Johnson and Goodpasture in 1934Frequent cause of outbreaks among military personnel in prevaccine era
D-r Mitova 50
Mumps Virus
ParamyxovirusRNA virusOne antigenic typeRapidly inactivated by chemical agents, heat and ultraviolet light
D-r Mitova 51
Mumps Pathogenesis
Respiratory transmission of virusReplication in nasopharynx and regional lymph nodesViremia 12-25 days after exposure with spread to tissuesMultiple tissues infected during viremia
D-r Mitova 52
Mumps Clinical FeaturesIncubation period 14-18 daysNonspecific prodrome of low-grade fever, headache, malaise, myalgiaParotitis in 30%-40%Up to 20% of infections asymptomaticMay present as lower respiratory illness, particularly in preschool-aged children
D-r Mitova 53
D-r Mitova 54
CNS involvement
Orchitis
Pancreatitis
Deafness
Death
15% of clinical cases
20%-50% in post- pubertal males
2%-5%
1/20,000
1-3/10,000
Mumps Complications
D-r Mitova 55
Mumps Laboratory Diagnosis
Isolation of mumps virusSerologic testing
positive IgM antibodysignificant increase in IgG antibody between acute and convalescent specimens
D-r Mitova 56
Mumps EpidemiologyReservoir Human
Transmission Respiratory drop nuclei Subclinical infections may transmit
Temporal pattern Peak in late winter–spring
Communicability Three days before to four days after onset of active
disease
D-r Mitova 57
Measles Mumps Rubella Vaccine
12 months is the recommended and minimum ageMMR given before 12 months should not be counted as a valid doseRevaccinate at >12 months of age
D-r Mitova 58
MMR IndicationsAll infants >12 months of age
Susceptible adolescents and adults without documented evidence of rubella immunity
Emphasis on non-pregnant women of childbearing age, particularly those born outside the U.S.
D-r Mitova 59
Second Dose Recommendation
First dose of MMR at 12-15 monthsSecond dose of MMR at 4-6 yearsSecond dose may be given any time >4 weeks after the first dose
D-r Mitova 60
MMR Adverse Reactions
Fever 5%-15%
Rash 5%
Joint symptoms 25%
Thrombocytopenia <1/30,000 doses
Parotitis rare
Deafness rare
Encephalopathy <1/1,000,000 doses
D-r Mitova 61
Severe allergic reaction to vaccine component or following prior dose
Pregnancy
Immunosuppression
Moderate or severe acute illness
Recent blood product
MMR VaccineContraindications and
Precautions
D-r Mitova 62
MMR Vaccine and Autism “The evidence favors a rejection of a
causal relationship at the population level between MMR vaccine and autism spectrum disorders (ASD).”
- Institute of Medicine, April 2001
D-r Mitova 63
Measles and Mumps Vaccines and Egg Allergy
Measles and mumps viruses grown in chick embryo fibroblast cultureStudies have demonstrated safety of MMR in egg allergic childrenVaccinate without testing
D-r Mitova 64
Measles Vaccine and HIV Infection
MMR recommended for persons with asymptomatic and mildly symptomatic HIV infectionNOT recommended for those with evidence of severe immuno- suppressionPrevaccination HIV testing not recommended
D-r Mitova 65
PPD and Measles Vaccine
Apply PPD at same visit as MMRDelay PPD >4 weeks if MMR given firstApply PPD first—give MMR when skin test read